Introduction
According to the global WHO statistics, 7.9 million deaths occur each year due to cancer. Of these deaths, around 70%, i.e. 5.5 million are now occurring in the developing world. Cancer of the cervix is the second most common cancer in women in the world, with an estimated 529,409 new cases and 274,883 deaths in 2008. 1 Bangladesh has the highest level of incidence and mortality rates due to cervical cancer among women. The prevalence of cervical cancer in women of Bangladesh is around 25-30%/100,000. 2 Bangladesh has a population of 50.19 million women aged 15 years and older who are at risk of developing cervical cancer. Current estimates indicate that every year in Bangladesh 17,686 women are diagnosed with cervical cancer and 10,364 die from the disease. Cervical cancer ranks as the second most frequent cancer in women of Bangladesh and the second most frequent cancer among women between 15 and 44 years of age. Data is not yet available on the human papilloma virus (HPV) burden in the general population of Bangladesh. However, in Southern Asia, the region Bangladesh belongs to, ~7.9% of women in the general population is estimated to harbor cervical HPV infection at a given time. 2 HPV infection is one of the most common sexually transmitted diseases. Roughly half of all cervical cancers worldwide contain the onco-gene HPV16; other important high risk types are HPV18, 45 and 31. 3 One study showed that the prevalence of HPV in sex workers of Bangladesh was 75.8% whereas for the high risk group it was 49.8%. The most prevalent high risk HPV types, in order of prevalence rate, were HPV16, HPV18, HPV58, HPV45, HPV31 and HPV33. Both HPV16 and HPV18 were present in 21% of the cases. 4 Cervical cancer is a preventable disease by screening and treatment of pre-invasive condition. Unfortunately, there is no effective screening program in Bangladesh. Risk factors for cervical cancer include early age at first intercourse, history of multiple sexual partners, and smoking. It is more common in low socio-economic classes. [5] [6] [7] A study done in Mumbai, India showed that nearly 70% of cervical cancer patients present at Stages III and IV of the disease. Around 20% of women who develop cervical cancer die within the first year of diagnosis and the 5 year relative survival rate is 50%. The majority of cases are squamous cell carcinoma and adenocarcinoma is less common. 8
Materials and method
This cross sectional study was carried out at oncology division of Delta Medical College and Hospital during the period of January to December 2011 to analyze the incidence, staging and treatment modalities of cancer cervix. Total 2264 female cancer patients were registered during the study period. Among them 523 (23%) patients with age ranges from 20-80 years were diagnosed as carcinoma of uterine cervix. All patients underwent gynecological examination in this centre and extent of the disease for each patient was documented, staging was done (where possible) according to FIGO staging. Routine and relevant investigations were performed.
All the patients except those who failed to continue the treatment were treated with external beam radiotherapy (EBRT) to pelvis either in this centre or in outside hospital. In this centre it was done either by LINAC or Co-60 machine. Prescribed EBRT dose was 46 to 50 Gy in 25 fractions over 5 weeks. Few patients who had pelvic lymph node metastases on CT scan were treated with extended field radiation to the para-aortic nodes also. Indicated patients received HDR brachytherapy with Co-60 BEBIG Multisource unit, installed first time in Bangladesh. 9 They received brachytherapy either with tandem and ovoids, vaginal cylinder, tandem and vaginal cylinder or interstitial application. 
Results
Among 2264 female cancer patients total 523 (23%) patients were diagnosed as having carcinoma cervix. Fig 7 shows the incidence of carcinoma cervix.
Regarding the age incidence majority (39.38%) of the patients were within 41-50 years of age group (Table I) . Table II shows the histopathological subtype of carcinoma cervix. Histopathologically most of the patients (93%) were diagnosed as squamous cell carcinoma, followed by adenocarcinoma (5.7%) and adeno-squamous cell carcinoma (1.1%). Among the patients 233 (44.55%) were referred to this centre postoperatively. Out of these referred cases 40 patients (17.18%) came with recurrence of disease at vault of vagina years after surgery. The time interval between surgery and development of recurrence was from 1-6 years. According to our institutional protocol locally advanced stages i.e. Stage IIB, IIIA, IIIB and IVA cases were treated with 7 Gy weekly in 3 fractions and few cases with 6 Gy weekly in 4 fractions using BEBIG Multisource HDR with Co-60 for postoperative patients who were in early stages of cancer. 9 They received 5 Gy in 2 fractions to the vault and upper third of the vagina each one week apart. High risk patients like histological high grade, cut margin involvement, Stage IIA received 6-7 Gy in 2-3 fractions.
Rectal and bladder doses were calculated according to ICRU-38 guidelines and were within permissible limits. Acute and late toxicities were within tolerable limits.
Out of 523 patients, 128 (24.47%) patients received concurrent chemotherapy with Inj. Cisplatin 40 mg/m 2 I/V weekly. Information regarding concurrent chemotherapy was not always available for patients which were referred from outside hospitals. Forty five patients (8.6%) referred from outside received neo-adjuvant chemotherapy prior to referral to this centre. Most of the patients (46%) could complete up to 5 cycles of chemotherapy and only 3% patients could complete the full 6 cycle schedule (Table V) . Many patients could not receive concurrent chemotherapy due to hematological and non-hematological toxicities or refused to continue chemotherapy. 
Discussion
This study revealed that the incidence of carcinoma cervix is 23% which almost represents the national data of Bangladesh. 2 Approximately 70-75% of cervical carcinomas are of squamous cell type and we also found a similar pattern. 11 Most of the carcinoma cervix patients were diagnosed at advanced stage and similar ovservation was made by Dinshaw et al. 8 It is advisable to start brachytherapy treatment within two weeks of completion of EBRT to get the maximum biological response, so patients should be referred for brachytherapy immediately after completion of EBRT. Concurrent chemotherapy should be given in advanced stages of carcinoma cervix as randomized clinical trials showed improved survival with concurrent chemo-radiation. 12,13 But this study explored that a major proportion of patients were sent for brachytherapy after a long delay after initial EBRT even after 7-8 months. It is the combined outcome of ignorance and scarcity of brachytherapy facility. It is to be mentioned that this specialized centre is equipped with both EBRT and brachytherapy facilities and also expertise for providing such sophisticated radiotherapies along with chemotherapy whenever needed. The study also revealed that a good proportion of patients were referred after surgery without providing documents of preoperative clinical staging. Some patients also came with recurrence which might be due to ignorance and lack of health awareness among the common people as well as health care providers or delay in referral.
In Bangladesh, cancer cervix is one of the leading cancers and cause of death in women 2 ; hence emphasis should be given on screening and early diagnosis. A national consensus for the treatment guidelines for carcinoma cervix is necessary. Proper gynecological examination and staging must be done before decision of treatment. Inadequate surgery like sub-total hysterectomy prevents the patients to receive curative treatment, especially brachytherapy, which is a very important part of the treatment of cervical cancer. It should be emphasized that treatment of cancer cervix must be a team work by gynaecologists and oncologists. So strict protocol should be followed for carcinoma cervix patients starting from initial evaluation and treatment and necessary referral thereafter.
